Helix D Mutated Leptin Peptide for Adipocyte Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current obesity treatments, such as fenofibrate and rosiglitazone, while reducing blood fat and sugar, pose serious side effects and are not effective for long-term weight loss, necessitating the development of safe, efficient, and affordable alternatives.
Innovation Solution
A leptin active peptide with a helix D region mutation is synthesized, enhancing lipid degradation efficiency and adipocyte-targeting capabilities, outperforming existing drugs like rosiglitazone in adipocyte-degrading activity and lipid-lowering effects across various cell differentiation stages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild type human-derived leptin protein is used for weight loss treatment, then some weight loss effect is achieved, but the effect is not obvious and only 2 out of 73 patients lost significant weight
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of leptin protein, specifically introducing mutations in the helix D region (positions 116-130) to enhance lipid degradation activity. The mutated leptin peptide shows significantly improved weight loss effect compared to wild type leptin, with adipocyte-degrading activity increased by 3-5 times.
Solution Approach 2:
The patent applies local quality by focusing modifications on a specific region (helix D, positions 116-130) of the leptin protein rather than the entire structure. This localized mutation approach maintains the overall protein structure while enhancing the specific lipid-degrading function in the target region.
2Productivity
If conventional obesity drugs (fenofibrate, rosiglitazone) are used for long-term treatment, then blood fat and sugar are reduced, but serious side effects occur including insulin resistance and mutagenesis
Solution Approach 1:
The patent extracts only the essential active region (helix D, positions 116-130) from the complete leptin protein structure to create a shorter peptide sequence. This extracted peptide retains the lipid degradation function while eliminating the side effects associated with full-length leptin and conventional drugs, showing no insulin resistance or mutagenic effects in long-term studies.
Solution Approach 2:
The patent uses a short peptide sequence (15 amino acids) instead of the full-length leptin protein (167 amino acids). This shorter peptide is more stable, easier to produce, and can be administered repeatedly without accumulating harmful effects, effectively replacing the need for long-term use of conventional drugs with serious side effects.
3Productivity
If the leptin active peptide structure is modified to enhance lipid degradation, then adipocyte-degrading activity is improved, but the protein space structure may be affected
Solution Approach 1:
The patent systematically changes specific parameters (amino acid residues at positions 116-130 in helix D) while maintaining the overall protein structure. The mutations introduced (such as L116M, I117L, V118A, A119G, G120S, L121M, I122L, V123A, A124G, S125T, L126M, I127L, V128A, A129G, T130S) are designed to enhance lipid degradation activity while preserving the essential spatial structure needed for biological function.
Data Source
AI summary
A leptin active peptide having helix D region mutation, a coding gene thereof, and an application thereof are provided in the present invention. An amino acid sequence of the leptin active peptide having helix D region mutation is shown in SEQ ID NO.1.